Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROCLIPI international Study.

BACKGROUND Early-stage mycosis fungoides (MF) includes patients with dermatopathic lymph nodes (LNs) or early lymphomatous LN involvement. There is lack of unanimity among current guidelines regarding the indications for initial staging imaging in early-stage presentation of MF in the absence of enlarged palpable LNs. METHODS Review of clinicopathologically confirmed newly diagnosed patients with cutaneous patch/plaque (T1/T2) MF from PROspective International Cutaneous Lymphoma Prognostic Index (PROCLIPI) data. RESULTS PROCLIPI enrolled 375 patients with T1/T2 MF: 304 classical-MF and 71 folliculotropic-MF. Imaging was performed in 169 patients (45%; 83=CT, 18=PET/CT, 68=U/S); only 9 (5%) had palpable enlarged (≥15mm) LNs, with an over-representation of plaques, irrespective of the 10% body-surface-area cutoff which distinguishes T1 from T2. Folliculotropic-MF was not more frequently imaged than classical-MF. Radiologically enlarged LNs (≥15mm) were detected in 30 patients (18%); only 7 had clinical lymphadenopathy. On multivariate analysis, plaque presentation was the sole parameter significantly associated with radiologically enlarged LNs. Imaging of only clinically enlarged LNs upstaged 4% of patients (7/169) to at least IIA, whereas non-selective imaging upstaged another 14% (24/169). LN biopsy, performed in 8/30, identified N3 (extensive lymphomatous involvement) in 2, and N1 (dermatopathic changes) in 6. CONCLUSION Physical examination was a poor determinant of LN enlargement/involvement. Presence of plaques was associated with significant increase in identification of enlarged/involved LN in patients with early-stage presentation of MF, which may be important when deciding who to image. Imaging increases detection rate of stage-IIA, and identifies rare cases of extensive lymphomatous nodes, upstaging them to advanced-stage IVA2.

[1]  D. Buckley,et al.  British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018 , 2018, The British journal of dermatology.

[2]  M. Weichenthal,et al.  The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patients , 2018, The British journal of dermatology.

[3]  J. Scarisbrick,et al.  Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. , 2018, European journal of cancer.

[4]  J. Scarisbrick,et al.  Computed tomography scanning in mycosis fungoides: optimizing the balance between benefit and harm , 2018, The British journal of dermatology.

[5]  R. Willemze,et al.  Clinical Staging and Prognostic Factors in Folliculotropic Mycosis Fungoides. , 2016, JAMA dermatology.

[6]  M. Feinmesser,et al.  New insights into folliculotropic mycosis fungoides (FMF): A single-center experience. , 2016, Journal of the American Academy of Dermatology.

[7]  J. Cayuela,et al.  Lymph node image‐guided core‐needle biopsy for cutaneous T‐cell lymphoma staging , 2016, The British journal of dermatology.

[8]  R. Cowan,et al.  Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Zinzani,et al.  Time course, clinical pathways, and long‐term hazards risk trends of disease progression in patients with classic mycosis fungoides , 2012, Cancer.

[10]  Wei Wei,et al.  Long-term Outcomes of 1,263 Patients with Mycosis Fungoides and Sézary Syndrome from 1982 to 2009 , 2012, Clinical Cancer Research.

[11]  J. Scarisbrick,et al.  Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Nicola Pimpinelli,et al.  Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). , 2007, Blood.

[13]  A. Varghese,et al.  Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. , 2003, Archives of dermatology.

[14]  B. Löwenberg,et al.  Ultrasound examination of pathological cervical lymph nodes in patients with non‐Hodgkin's lymphoma and Hodgkin's disease , 1994, British journal of haematology.

[15]  C. Balu-Maestro,et al.  Lymphomatous superficial lymph nodes: US detection. , 1987, Radiology.